MedTrace Logo

Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects

NCT03175835 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-07-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the drug interaction between CKD-519 and rosuvastatin in healthy male subjects.

Conditions

  • Dyslipidemias

Interventions

DRUG

Rosuvastatin 20 mg

Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1\~Day5

DRUG

CKD-519 200 mg

Treatment B: CKD-519 200 mg(100 mg X 2 tablets) for Day9\~Day21

DRUG

Rosuvastatin 20 mg & CKD-519 200 mg

Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22\~Day26

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-08
Primary Completion
2017-06-19
Completion
2017-06-19

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03175835 on ClinicalTrials.gov